Connor, Clark & Lunn Investment Management (CC&L)

Connor, Clark & Lunn Investment Management (CC&L)’s Kinnate Biopharma Inc. Common Stock KNTE Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio KNTE Stock Details KNTE Fund Activity

Upgrade to unlock

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell
2023 Q4	$182K	Buy
2023 Q3	$73K	Buy